Merck Reports Phase 3 KEYNOTE-024 Results for Keytruda in PD-L1 High NSCLC

Merck today announced results from the Phase 3 KEYNOTE-024 trial evaluating Keytruda (pembrolizumab) versus platinum-based chemotherapy in patients with previously untreated metastatic non-small cell lung cancer with PD-L1 TPS ≥50%. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with Keytruda. These results led to FDA approval of Keytruda as first-line treatment for PD-L1 high NSCLC.